Clovis Oncology receives positive trend vote from CHMP in European regulatory review
Clovis Oncology announced an update to the ongoing regulatory review for the MAA for rucaparib tablets as monotherapy for treatment of a limited population of advanced ovarian cancer patients with deleterious BRCA mutation (germline and/or somatic). February 21, 2018